

Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:
Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:


Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:
Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:


Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:
Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers:


Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers, using or not external aggressors (LPS, histamine, UV, PMA):
Dermaclaim has different in vitro models at your disposal:
We can evaluate the following biomarkers, using or not external aggressors (PM, heavy metals, PHA):


Dermaclaim has different in vitro models at your disposal:
We can evaluate dermal penetration using immunohistochemistry after including fluorophores (fluorescein, rhodamine..) in the tested formulation, using different stainings
Dermaclaim has different in vitro models at your disposal:
We can evaluate the whole human transcriptomics or targeted-qPCR for specific panels of genes:


Type I and III collagens form the principal dermal fibrillar scaffold, while additional collagen families regulate fibrillogenesis, tissue architecture, mechanical properties and dermal–epidermal cohesion. A multi-collagen profile therefore provides a broader mechanistic view than the assessment of COL1A1 alone, what could be assessed on:
We can evaluate the stimulating capacity on collagen ecosystem (10 different collagens), through gene expression assessment using qPCR or protein synthesis quantification using ELISA: